Company intelligence / Profile preview

SVF Vaccines

Ownership: Private
Development stage: Phase 1

Overview

SVF Vaccines develops next-generation vaccines and immunotherapies for life-threatening infectious diseases using proprietary technology from the Karolinska Institute. Its lead candidate, SVF‑002—a universal COVID‑19 DNA vaccine—entered Phase I trials in collaboration with the OpenCorona consortium at Karolinska University Hospital. The company also has preclinical programs targeting chronic hepatitis B/D and Crimean Congo Hemorrhagic Fever. Early clinical data show strong antibody and T-cell responses against SARS-CoV‑2 variants.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccinesTherapeutic proteinsProphylactic vaccinesSynthetic peptides
Industry: Biotech

Drug pipeline

10 assets

SVF-002

Preclinical

9 more assets in the full pipeline.

Partnerships

Karolinska InstitutetOpenCorona consortium (EU Horizon 2020 funding)phase 1 unit at Karolinska University Hospital

Beyond the preview

Go deeper on SVF Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVF Vaccines.